I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Asao, Tetsuhiko
28
results:
OpenAccess-fulltext X
Search for persons
X
Sorted by: Relevance
Sorted by: Year
?
1
Usefulness of Computed Tomography for Evaluating the Effect..:
Abe, Sumiko
;
Yasuda, Mina
;
Tobino, Kazunori
...
info:eu-repo/semantics/altIdentifier/doi/10.2147/JAA.S452865. , 2024
Link:
https://www.dovepress.co..
?
2
Pemetrexed for advanced non-small cell lung cancer patients..:
Kato, Motoyasu
;
Shukuya, Takehito
;
Takahashi, Fumiyuki
...
http://www.biomedcentral.com/1471-2407/14/508. , 2014
Link:
http://www.biomedcentral..
?
3
Supplementary Table S5 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S5_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415543. , 2024
Link:
https://doi.org/10.1158/..
?
4
Supplementary Figure S2 from Phase II Study of Durvalumab I..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Figure_S2_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415561. , 2024
Link:
https://doi.org/10.1158/..
?
5
Supplementary Table S2 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S2_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415552. , 2024
Link:
https://doi.org/10.1158/..
?
6
Supplementary Table S3 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S3_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415549. , 2024
Link:
https://doi.org/10.1158/..
?
7
Supplementary Figure S3 from Phase II Study of Durvalumab I..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Figure_S3_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415558. , 2024
Link:
https://doi.org/10.1158/..
?
8
Supplementary Table S6 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S6_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415540. , 2024
Link:
https://doi.org/10.1158/..
?
9
Supplementary Table S1 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415555. , 2024
Link:
https://doi.org/10.1158/..
?
10
Supplementary Table S4 from Phase II Study of Durvalumab Im..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Table_S4_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415546. , 2024
Link:
https://doi.org/10.1158/..
?
11
Supplementary Figure S1 from Phase II Study of Durvalumab I..:
Shinji Nakamichi
;
Kaoru Kubota
;
Toshihiro Misumi
...
https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Phase_II_Study_of_Durvalumab_Immediately_after_Completion_of_Chemoradiotherapy_in_Unresectable_Stage_III_Non_small_Cell_Lung_Cancer_TORG1937_DATE_Study_/25415564. , 2024
Link:
https://doi.org/10.1158/..
?
12
Early Detection of Therapeutic Benefit from PD-1/PD-L1 Bloc..:
Shiting Xu
;
Keita Miura
;
Takehito Shukuya
...
https://www.mdpi.com/2072-6694/15/4/1170. , 2023
Link:
https://doi.org/10.3390/..
?
13
Pneumonitis associated with pembrolizumab plus chemotherapy..:
Daichi Fujimoto
;
Satoru Miura
;
Keisuke Tomii
...
https://doi.org/10.1038/s41598-023-30676-y. , 2023
Link:
https://doi.org/10.1038/..
?
14
Early Detection of Therapeutic Benefit from PD-1/PD-L1 Bloc..:
Shiting Xu
;
Keita Miura
;
Takehito Shukuya
...
https://dx.doi.org/10.3390/cancers15041170. , 2023
Link:
https://doi.org/10.3390/..
?
15
CALML5 is a novel diagnostic marker for differentiating thy..:
Koichiro Kanamori
;
Kentaro Suina
;
Takehito Shukuya
...
https://doi.org/10.1111/1759-7714.14853. , 2023
Link:
https://doi.org/10.1111/..
1-15
